A Single Arm, Open Label, Phase 1b/2 Study of Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
Latest Information Update: 30 Apr 2024
At a glance
- Drugs PLX 51107 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 23 Apr 2024 Status changed from completed to discontinued.
- 13 Feb 2024 Status changed from recruiting to completed.
- 24 Mar 2022 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.